ZAI Lab (Shanghai) Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2014-01-06
- Employees
- -
- Market Cap
- -
- Website
- http://www.zailaboratory.com
A Study of ZL-1310 in Participants With Selected Solid Tumors
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT06885281
- Locations
- 🇺🇸
Zai Lab Site 2001, San Francisco, California, United States
🇺🇸Zai Lab Site 2002, New York, New York, United States
🇺🇸Zai Lab Site 2024, Cleveland, Ohio, United States
An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT06179069
- Locations
- 🇪🇸
Zai Lab Site 8007, Barcelona, Spain
🇪🇸Zai Lab Site 8009, Madrid, Spain
🇪🇸Zai Lab Site 8008, Málaga, Spain
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
- Conditions
- Solid Malignancies
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05866354
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shangdong, China
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05263986
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
- Conditions
- Untreated Mucosal or Acral Lentiginous MelanomaUnresectable, Recurrent or Metastatic Melanoma
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT04653038
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- Conditions
- Gastrointestinal Stromal Tumor(GIST)
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT04633122
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳The General Hospital of Peking University, Beijing, Beijing, China
A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04398108
- Locations
- 🇨🇳
The fifth medical center of the General Hospital of people's Liberation Army of China, Beijing, Beijing, China
🇨🇳The fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of Niraparib in Patients With Relapsed Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Drug: ZL-2306(Niraparib）
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT04392102
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT04282980
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
🇨🇳Union Medical College Hospital, Chongqing Medical University, Chongqing, Chongqing, China
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
- Conditions
- Breast Cancer Metastatic
- Interventions
- Drug: Chosen Chemotherapy (Capecitabine)Drug: Chosen Chemotherapy (Vinorelbine )Drug: Chosen Chemotherapy (Gemcitabine )
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 123
- Registration Number
- NCT04262804
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan